| Step | Dilution Factor | Cumulative Dilution | Sample Vol (mL) | Diluent Vol (mL) | Status |
|---|
MVD is the maximum allowable dilution of a sample that still permits detection of endotoxin at the endotoxin limit concentration. It is calculated as MVD = (Endotoxin Limit × Concentration) / Lambda, where Lambda is the labeled lysate sensitivity. Diluting beyond MVD would make the test unable to detect endotoxin at the limit level.
LAL (Limulus Amebocyte Lysate) is derived from horseshoe crab blood and detects endotoxin through a clotting cascade. rFC (recombinant Factor C) is a synthetic alternative that uses a recombinant version of the Factor C protein. rFC assays are more specific (they do not react to beta-glucans), more sustainable, and increasingly accepted by regulatory agencies including FDA and EMA.
USP <85> defines endotoxin limit K values by route: IV drugs use K=5 EU/kg/hr, intrathecal products use K=0.2 EU/kg/hr (most stringent due to CNS sensitivity), and medical devices use 0.5 EU/device. The endotoxin limit (EL) for a drug is calculated as EL = K / M, where M is the maximum dose per kg of body weight per hour.
A PPC test validates that the sample matrix does not interfere with endotoxin detection. A known amount of endotoxin (typically 2 lambda) is spiked into the diluted sample. Recovery must be 50-200% of the expected value per USP <85>. If recovery falls outside this range, further dilution or sample treatment is needed to overcome matrix interference.
One Endotoxin Unit (EU) is approximately equivalent to 100 pg of E. coli reference standard endotoxin (EC-6). EU/mL measures endotoxin concentration in solution. EU/mg relates endotoxin to drug substance weight. For injectable drugs, limits are typically expressed as EU/mL, EU/mg, or EU/kg body weight/hour depending on the regulatory context.
USP <85> (Bacterial Endotoxins Test) is the compendial standard for detecting and quantifying gram-negative bacterial endotoxins in pharmaceutical products. Endotoxins (lipopolysaccharides) can cause fever, hypotension, and organ failure. Compliance with USP <85> is required by the FDA for release testing of all parenteral drugs, biological products, and medical devices that contact blood or cerebrospinal fluid.
The MVD is the maximum dilution at which product endotoxin at the specification limit is still detectable, so it sits right at the edge of the assay's detection range. Testing one 2-fold step more concentrated than the maximum (commonly MVD/2) leaves a safety margin so a borderline sample stays on-scale rather than at the limit of detection. It also keeps enough dilution to overcome assay inhibition or enhancement, giving a valid, defensible result instead of testing at the very edge of detection.